Open Access

Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines

  • Silvia Boero1,
  • Anna Morabito2,
  • Barbara Banelli2,
  • Barbara Cardinali3,
  • Beatrice Dozin4,
  • Gianluigi Lunardi5,
  • Patrizia Piccioli6,
  • Sonia Lastraioli7,
  • Roberta Carosio2,
  • Sandra Salvi8,
  • Alessia Levaggi3,
  • Francesca Poggio9,
  • Alessia D’Alonzo3,
  • Massimo Romani2,
  • Lucia Del Mastro3,
  • Alessandro Poggi1 and
  • Maria Pia Pistillo2Email author
Journal of Translational Medicine201614:24

Published: 22 January 2016

The original article was published in Journal of Translational Medicine 2015 13:324

Erratum to: J Transl Med (2015) 13:324 DOI 10.1186/s12967-015-0680-0

It has come the publisher’s attention that the original version of this article [1] unfortunately contained an error. In Table 3, first column, the FcγRIIA 131 H>R genotypes were incorrectly labelled. In particular, V/V should have read H/H, V/F should have read H/R and F/F should have read R/R. Please note that this correction does not change the genotype numerical values of FcγRIIA polymorphism. The correct Table 3 has been published as Table 1 in this Erratum.
Table 1

Genotypic and allelic frequencies of FcγRIIIA and FcγRIIA polymorphisms in breast cancer patients and healthy controls


n (%)

P *


n (frequency)

NEO (n = 15)

MTS (n = 10)

CTR (n = 33)

NEO (2n = 30)

MTS (2n = 20)

CTR (2n = 66)






4 (26.7)

3 (30.0)

6 (18.2)



13 (0.43)

8 (0.40)

26 (0.39)



5 (33.3)

2 (20.0)

14 (42.4)



17 (0.57)

12 (0.60)

40 (0.60)



6 (40.0)

5 (50.0)

13 (39.4)



P = 0.213

P = 0.065

P = 0.522


FcγRIIA 131H>R


FcγRIIA 131H>R



3 (20.0)

4 (40.0)

9 (27.3)



14 (0.47)

10 (0.50)

35 (0.53)



8 (53.3)

2 (20.0)

17 (51.5)



16 (0.53)

10 (0.50)

31 (0.47)



4 (26.7)

4 (40.0)

7 (21.2)



P = 0.782

P = 0.058



Genotyping of FcγRIIIA 158V>F was performed by a newly developed PSQ method after pre-amplification of FcγRIIIA gene. Genotyping of FcγRIIA 131H>R was performed by T-ARMS PCR and SBT. Conventionally, the 158V>F variant corresponds to the G>T SNP [i.e. guanine corresponding to valine (V) and thymine corresponding to phenylalanine (F)] and the 131H>R SNP corresponds to the A>G SNP [i.e. adenine corresponding to histidine (H) and guanine corresponding to arginine (R)]

Comparison of FcγR genotypic and allelic frequencies between patients and control subjects was estimated using the Pearson’s χ2 test (P* value) and the Fisher’s test (P° value), respectively. Statistical significance: P < 0.05

NEO neoadjuvant, MTS metastatic, CTR controls, HWE Hardy–Weinberg equilibrium. HWE was tested by the Pearson’s χ2 test (P < 0.05 indicates lack of HWE)



Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Unit of Molecular Oncology and Angiogenesis, IRCCS AOU San Martino-IST
Unit of Tumor Epigenetics, IRCCS AOU San Martino-IST
Development of Innovative Therapies Unit, IRCCS AOU San Martino-IST
Clinical Epidemiology Unit, IRCCS AOU San Martino-IST
Medical Oncology Unit, Sacro Cuore Don Calabria Hospital
Cellular Biology Unit, IRCCS AOU San Martino-IST
Laboratory of Molecular Diagnostics, IRCCS AOU San Martino-IST
Unit of Pathology, IRCCS AOU San Martino-IST
Unit of Medical Oncology 2, IRCCS AOU San Martino-IST


  1. Boero S, Morabito A, Banelli B, Cardinali B, Dozin B, Lunardi G, Piccioli P, Lastraioli S, Carosio R, Salvi S, Levaggi A, Poggio F, D’Alonzo A, Romani M, Del Mastro L, Poggi A, Pistillo MP. Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines. J Transl Med. 2015;13:324.PubMed CentralView ArticlePubMedGoogle Scholar


© Boero et al. 2016